Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 4387286, 7 pages
http://dx.doi.org/10.1155/2016/4387286
Clinical Study

Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China

1Department of Ophthalmology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China
2Department of Ophthalmology, Beijing Children’s Hospital, Capital Medical University, 56 Nanlishi Road, Xicheng District, Beijing 100045, China

Received 20 October 2015; Revised 29 December 2015; Accepted 12 January 2016

Academic Editor: Ji-jing Pang

Copyright © 2016 Xunda Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Aerts, L. Lumbroso-Le Rouic, M. Gauthier-Villars, H. Brisse, F. Doz, and L. Desjardins, “Retinoblastoma,” Orphanet Journal of Rare Diseases, vol. 1, article 31, 2006. View at Publisher · View at Google Scholar
  2. C. L. Shields, A. Mashayekhi, A. K. Au et al., “The international classification of retinoblastoma predicts chemoreduction success,” Ophthalmology, vol. 113, no. 12, pp. 2276–2280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. L. Shields, A. Ramasubramanian, A. Thangappan et al., “Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes,” Ophthalmology, vol. 116, no. 3, pp. 544–551, 2009. View at Publisher · View at Google Scholar
  4. Y. P. Gobin, I. J. Dunkel, B. P. Marr, S. E. Brodie, and D. H. Abramson, “Intra-arterial chemotherapy for the management of retinoblastoma four-year experience,” Archives of Ophthalmology, vol. 129, no. 6, pp. 732–737, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Schaiquevich, A. Ceciliano, N. Millan et al., “Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma,” Pediatric Blood and Cancer, vol. 60, no. 5, pp. 766–770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Francis, P. Schaiquevich, E. Buitrago et al., “Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study,” Ophthalmology, vol. 121, no. 9, pp. 1810–1817, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Ericson and B. H. Rosengren, “Present therapeutic resources in retinoblastoma,” Acta Ophthalmologica, vol. 39, no. 4, pp. 569–576, 1961. View at Publisher · View at Google Scholar
  8. Z. A. Karcioglu, “Fine needle aspiration biopsy (FNAB) for retinoblastoma,” Retina, vol. 22, no. 6, pp. 707–710, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Suzuki and A. Kaneko, “Vitreous injection therapy of melphalan for retinoblastoma,” in Proceedings of the 15th Biannual Meeting, International Society of Ocular Oncology, Buenos Aires, Argentina, November 2011.
  10. S. Tuncer, Ö. Balci, B. Tanyildiz, R. Kebudi, and C. L. Shields, “Intravitreal lower-dose (20 μg) melphalan for persistent or recurrent retinoblastoma vitreous seeds,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 46, no. 9, pp. 942–948, 2015. View at Publisher · View at Google Scholar
  11. F. L. Munier, M.-C. Gaillard, A. Balmer, and M. Beck-Popovic, “Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives,” Saudi Journal of Ophthalmology, vol. 27, no. 3, pp. 147–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Francis, D. H. Abramson, M. Gaillard, B. P. Marr, M. Beck-Popovic, and F. L. Munier, “The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan,” Ophthalmology, vol. 122, no. 6, pp. 1173–1179, 2015. View at Publisher · View at Google Scholar
  13. F. L. Munier, M. C. Gaillard, A. Balmer et al., “Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications,” British Journal of Ophthalmology, vol. 96, no. 8, pp. 1078–1083, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Suzuki, Y. Aihara, M. Fujiwara, S. Sano, and A. Kaneko, “Intravitreal injection of melphalan for intraocular retinoblastoma,” Japanese Journal of Ophthalmology, vol. 59, no. 3, pp. 164–172, 2015. View at Publisher · View at Google Scholar
  15. F. Ghassemi, C. L. Shields, H. Ghadimi, A. Khodabandeh, and R. Roohipoor, “Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma,” JAMA Ophthalmology, vol. 132, no. 8, pp. 936–941, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. H. Francis, X. L. Xu, Y. P. Gobin, B. P. Marr, S. E. Brodie, and D. H. Abramson, “Death by water: precautionary water submersion for intravitreal injection of retinoblastoma eyes,” The Open Ophthalmology Journal, vol. 8, pp. 7–11, 2014. View at Publisher · View at Google Scholar
  17. F. Ghassemi and C. L. Shields, “Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma,” Archives of Ophthalmology, vol. 130, no. 10, pp. 1268–1271, 2012. View at Publisher · View at Google Scholar · View at Scopus